Document Type : Letter to Editor
Authors
1 Student Research Committee, Baqiyatallah University of Medical Science, Tehran, Iran
2 Trauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
We have read a recent article about intravitreal pharmacotherapy for the treatment of macular edema secondary to branch retinal vein occlusion (BRVO) with great interest. You have mentioned that few studies have evaluated the efficacy of pegaptanib in ocular diseases; thus, discussing this the Food and Drug Administration (FDA)-approved drug is necessary.
Anti-VEGF therapy is a critical and potent approach for the management of macular edema. Anti-VEGF agents neither cause ruined alterations as lasers do, nor induce cataract formation as steroids do... (Read more...)
)
